SightfileU.S. market data from official filings

THERAVANCE BIOPHARMA INC (TBPH)

Name: THERAVANCE BIOPHARMA INC (TBPH) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001583107 · EDGAR filings · Updated 2026-07-08

THERAVANCE BIOPHARMA INC (TBPH) has reported institutional ownership of 96.6%, with 171 institutional managers holding positions valued at $808.4M per the latest 13F reporting period.

Institutional ownership

96.6%

Institutional managers

171

Reported 13F value

$808.4M

Insider activity

52 trans.

−$3.90M net selling

Latest updates

2026-07-08 — Insider transaction reported (Form 4)
2026-07-01 — Insider transaction reported (Form 4)
2026-06-29 — DEFA14A filed
2026-06-29 — Current report (8-K) filed
2026-06-23 — Insider transaction reported (Form 4)
2026-06-23 — Current report (8-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, THERAVANCE BIOPHARMA INC has 171 institutional holders and institutional ownership of 96.6%.

Insider activity

Insiders reported 52 transactions (0 buys, 19 sells) across 12 reporting insiders, with a net reported value of −$3.90M.

Related companies

SONIDA SENIOR LIVING INC (SNDA) · UROGEN PHARMA LTD (URGN) · JANUX THERAPEUTICS INC (JANX) · EVOMMUNE INC (EVMN) · PHATHOM PHARMACEUTICALS INC (PHAT) · HARROW INC (HROW)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-08.